Beauty Health (SKIN)
NASDAQ:SKIN
Want to see SKIN full AI Analyst Report?
Top Page
Beauty Health
(NASDAQ:SKIN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.63
▼(-30.33% Downside)
Action:Reiterated
Date:05/13/26
The score is held down primarily by high leverage and ongoing net losses despite positive free cash flow, alongside a clear downtrend in the stock’s technical setup. Offsetting factors include improving profitability metrics (EBITDA beat and strong margins) and maintained EBITDA guidance, but revenue weakness and reduced sales outlook keep the overall profile below average.
Positive Factors
Strong liquidity and cash generation
A $204M cash balance plus management guidance for modest positive FCF in coming quarters gives the company runway to execute commercial fixes and product initiatives. Durable liquidity reduces near-term refinancing risk and supports capex, R&D and working-capital needs while deleveraging is pursued.
Negative Factors
Very high leverage
Extremely elevated leverage limits financial flexibility and heightens execution risk; modest equity means cash flow must prioritize debt service. This constrains capital allocation, lengthens recovery timelines, and raises refinancing risk around the October 2026 maturity if cash flow or market access weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong liquidity and cash generation
A $204M cash balance plus management guidance for modest positive FCF in coming quarters gives the company runway to execute commercial fixes and product initiatives. Durable liquidity reduces near-term refinancing risk and supports capex, R&D and working-capital needs while deleveraging is pursued.
Read all positive factors
Beauty Health (SKIN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$78.49M
Dividend YieldN/A
Average Volume (3M)1.04M
Price to Earnings (P/E)―
Beta (1Y)1.89
Revenue Growth-8.16%
EPS Growth85.14%
CountryUS
Employees769
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.05
Shares Outstanding129,600,040
10 Day Avg. Volume926,645
30 Day Avg. Volume1,036,656
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)2.88
Price to Sales (P/S)0.58
P/FCF Ratio4.72
Enterprise Value/Market Cap3.19
Enterprise Value/Revenue0.85
Enterprise Value/Gross Profit1.30
Enterprise Value/Ebitda5.85
Forecast
1Y Price Target
$1.50Price Target Upside64.84% Upside
Rating ConsensusHold
Number of Analyst Covering5
EPS Forecast (FY)-0.15
Revenue Forecast (FY)$289.90M
Beauty Health Business Overview & Revenue Model
Company Description
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company's flagship product includes HydraFacial that enhance the skin to cleanse, peel, exfoliate, extract, infuse, an...
How the Company Makes Money
Beauty Health primarily makes money through a recurring “razor-and-blades” model tied to the HydraFacial platform. (1) Consumables sales: After a provider installs a HydraFacial system, each treatment requires single-use items (e.g., tips) and sol...
Beauty Health Earnings Call Summary
Earnings Call Date:May 07, 2026
(Q1-2026)
| Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Neutral
The call presented a balanced picture: operational and financial discipline produced a notable EBITDA beat, margin expansion, improved installed base metrics, and strong liquidity, but top-line performance remains pressured with declining sales, softer device placements, and structural macro/competitive headwinds. Management is taking concrete commercial and product actions and maintained EBITDA guidance while trimming revenue expectations, positioning 2026 as an execution/stabilization year with recovery expected in 2027.Positive Updates
Adjusted EBITDA Outperformance
Adjusted EBITDA of $8.5M in Q1, up 17% year-over-year and representing a 13.1% margin; result was well above the prior guidance range of $3.5M to $5.5M.
Negative Updates
Revenue Decline and Guidance Reduction
Total net sales of $64.9M in Q1, down 6.7% year-over-year and within guidance, but full-year revenue guidance was lowered to $280M–$295M from $285M–$305M (approximately a ~2.5% reduction or roughly $7.5M midpoint cut).
Read all updates
Q1-2026 Updates
Positive
Negative
Adjusted EBITDA Outperformance
Adjusted EBITDA of $8.5M in Q1, up 17% year-over-year and representing a 13.1% margin; result was well above the prior guidance range of $3.5M to $5.5M.
Read all positive updates
Company Guidance
Management revised full‑year revenue to $280–$295 million (about a 2.5% reduction, ~ $7.5M at the midpoint) while reiterating adjusted EBITDA of $35–$45 million; Q2 revenue is guided to $72–$77M with adjusted EBITDA of $11–$13M. In Q1 they reported net sales of $64.9M (down 6.7% YoY), consumables $46.4M (‑6.1%), delivery systems $18.5M (‑8.3%) with 746 systems placed (vs. 862 in Q1 2025), adjusted EBITDA $8.5M (13.1% margin, +17% YoY and well above prior Q1 guidance of $3.5–$5.5M), adjusted gross margin 72.2%, an active installed base of 36,400 systems (up 4% YoY) and device churn down 40% YoY. The company ended the quarter with $204.4M cash, faces an October 2026 debt maturity of ~ $103M, expects FY CapEx of $8–$10M (Q1 spend ~$1.6–$1.7M), anticipates modest positive free cash flow in the last three quarters and forecasts working capital to be relatively flat.Beauty Health Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
28
Negative
Cash Flow
62
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 296.11M | 300.79M | 334.29M | 397.99M | 365.88M | 260.09M |
| Gross Profit | 192.18M | 196.36M | 182.30M | 155.11M | 248.78M | 178.54M |
| EBITDA | 42.81M | 38.74M | 10.34M | -53.56M | 81.60M | -350.93M |
| Net Income | -6.02M | -9.52M | -29.10M | -100.12M | 44.22M | -378.76M |
Balance Sheet | ||||||
| Total Assets | 473.20M | 499.80M | 685.68M | 929.11M | 1.00B | 1.22B |
| Cash, Cash Equivalents and Short-Term Investments | 204.40M | 232.70M | 370.06M | 523.02M | 568.20M | 901.89M |
| Total Debt | 367.20M | 378.70M | 568.16M | 752.29M | 751.79M | 746.41M |
| Total Liabilities | 418.00M | 438.70M | 633.88M | 869.72M | 836.03M | 916.51M |
| Stockholders Equity | 55.20M | 61.10M | 51.80M | 59.39M | 167.05M | 302.30M |
Cash Flow | ||||||
| Free Cash Flow | 28.45M | 37.18M | 9.34M | 8.70M | -123.99M | -43.98M |
| Operating Cash Flow | 28.93M | 37.50M | 16.13M | 21.75M | -106.60M | -28.36M |
| Investing Cash Flow | -5.67M | -5.16M | -6.79M | -31.51M | -18.87M | -37.73M |
| Financing Cash Flow | -195.58M | -174.90M | -158.34M | -37.45M | -205.24M | 959.03M |
Beauty Health Technical Analysis
Negative
0.91
Price Trends
0.91
Negative
1.10
Negative
1.42
Negative
Market Momentum
-0.08
Positive
39.04
Neutral
20.58
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SKIN, the sentiment is Negative. The current price of 0.91 is above the 20-day moving average (MA) of 0.78, above the 50-day MA of 0.91, and below the 200-day MA of 1.42, indicating a bearish trend. The MACD of -0.08 indicates Positive momentum. The RSI at 39.04 is Neutral, neither overbought nor oversold. The STOCH value of 20.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SKIN.
Beauty Health Risk Analysis
Beauty Health disclosed 95 risk factors in its most recent earnings report. Beauty Health reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Beauty Health Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
55 Neutral | $557.02M | -1.83 | -94.52% | ― | -5.93% | -823.81% | |
54 Neutral | $284.51M | 47.78 | 6.84% | 2.39% | -14.17% | ― | |
51 Neutral | $88.29M | -21.87 | 10.50% | ― | 5.76% | -73.80% | |
47 Neutral | $743.75M | -23.40 | -4.17% | 3.51% | -5.30% | -196.78% | |
45 Neutral | $78.49M | -4.31 | -9.41% | ― | -8.16% | 85.14% |
* Consumer Defensive Sector Average
SKIN
Beauty Health
0.68
-0.88
-56.60%
HELE
Helen Of Troy
23.95
-2.99
-11.10%
NUS
Nu Skin
5.84
-1.26
-17.75%
EPC
Edgewell Personal Care
16.94
-9.69
-36.39%
SLSN
Solesence
1.36
-2.54
-65.13%
Beauty Health Corporate Events
Delistings and Listing ChangesRegulatory Filings and Compliance
Beauty Health Receives Nasdaq Notice on Bid Price
Negative
May 12, 2026
On May 8, 2026, SkinHealth Systems Inc. disclosed that it had received a notice from Nasdaq stating its Class A common stock had failed to meet the exchange’s minimum bid price requirement, after trading below $1.00 for 30 consecutive busine...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Beauty Health announces departure of chief revenue officer
Negative
May 6, 2026
On May 5, 2026, SkinHealth Systems Inc. terminated the employment of Chief Revenue Officer Ronald Menezes without cause, stating that his departure was not due to any disagreement related to financial reporting, operations, policies or practices. ...
Business Operations and StrategyExecutive/Board Changes
SkinHealth Systems unveils new corporate identity and strategy
Positive
Apr 22, 2026
On April 17, 2026, the company expanded its board from nine to eleven directors and appointed medical device operations executive Kenneth Tripp, plastic surgeon and aesthetics innovator Dr. Sachin Shridharani, and veteran beauty and consumer-produ...
Business Operations and StrategyLegal Proceedings
Beauty Health Advances Governance Settlement Over Syndeo Launch
Negative
Mar 6, 2026
On March 3, 2026, The Beauty Health Company notified stockholders that on February 9, 2026, it had entered into a stipulation of settlement, subject to Delaware Court of Chancery approval, to resolve a consolidated stockholder derivative action al...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.